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The importance of heparan sulfate proteoglycans (HSPGs) in neurodevelopment is becoming increasingly clear. However, studies on HSPGs are
hampered by pleiotropic effects when synthesis or modification of heparan sulfate itself is targeted, and by redundancy when the core proteins are
altered. Gain-of-function experiments can sometimes circumvent these issues. Here we establish that transgenic mice overexpressing the HSPG
agrin have severe ocular dysgenesis. The defects occur through a gain-of-function mechanism and penetrance is dependent on agrin dosage. The
agrin-induced developmental defects are highly variable, and include anophthalmia, persistence of vitreous vessels, and fusion of anterior chamber
structures. A frequently observed defect is an optic stalk coloboma leading to the misdifferentiation of the optic stalk as retina, which becomes
continuous with the forebrain. The defects in optic-stalk differentiation correlate with reduced sonic hedgehog immunoreactivity and overexpansion
of the PAX6 domain from the retina into the optic stalk. The ocular phenotypes associated with agrin overexpression are dependent on genetic
background, occurring with high penetrance in inbred C57BL/6J mice. Distinct loci sensitizing C57BL/6J mice to agrin-induced dysgenesis were
identified. These results indicate that agrin overexpression will provide a tool to explore the molecular interactions of the extracellular matrix and
cell surface in eye development, and provide a means for identifying modifier loci that sensitize mice to developmental eye defects.
© 2006 Elsevier Inc. All rights reserved.Keywords: Retina; Pax6; Sonic hedgehog; Heparan sulfate proteoglycan; Genetic modifiers; Development; DysgenesisIntroduction
The functional importance of proteoglycans in a variety of
developmental signaling events is well documented (Perrimon
and Bernfield, 2000, 2001). Heparan sulfate proteoglycans
(HSPGs) consist of a core protein with heparan sulfate (HS)
post-translationally added to serine residues. Variations in the
chemistry of this modification make it potentially extremely
information dense (Turnbull et al., 2001) and the synthesis of
HS is functionally critical for development. Eliminating HS
synthesis in mice results in embryonic lethality at 6 days of
gestation (E6) (Stickens et al., 2005). Tissue-specific deletion
of HS synthesis in the nervous system results in numerous
defects in morphogenesis and axon pathfinding (Inatani et al.,
2003). In zebrafish, retinal axon sorting is affected by elimi-
nation of HS synthesis, though earlier developmental events⁎ Corresponding author. Fax: +1 207 288 6077.
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doi:10.1016/j.ydbio.2006.11.033may progress based on maternal contribution of mRNA,
protein, and HS itself (Lee et al., 2004). More selective
phenotypes are generated by chemical treatments or the
elimination of enzymes that modify HS chains after they are
synthesized (Bulow and Hobert, 2004; Grobe et al., 2005; Irie
et al., 2002). The specificity of these effects has led to the
hypothesis that a “Heparan code” exists, in which region-
specific HS modifications encode spatial information required
for neurodevelopment (Bulow and Hobert, 2004; Holt and
Dickson, 2005).
Heparan sulfate influences many developmental signaling
pathways, including Fibroblast growth factors (FGFs), Hedge-
hog (Hh), Wingless (Wnt) and Transforming growth factor β
(TGF-β) (Baeg and Perrimon, 2000; Perrimon and Bernfield,
2000; Selleck, 2000). In addition to these broad developmental
signaling systems, HS affects neuronal development and axon
outgrowth through Semaphorin, LAR receptor tyrosine phos-
phatase, and Slit/Robo pathways (Fox and Zinn, 2005; Johnson
et al., 2004; Kantor et al., 2004).
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developing eye and retina provide excellent models for the
study of these pathways in morphogenesis, axon pathfinding
and cell migration (Chow and Lang, 2001). In the mouse, eye
development begins as an outgrowth of the telencephalon at
approximately E8.5. This initiates a cascade of inductive events
in which the neuroectoderm induces the surface ectoderm to
become the lens. Through morphogenetic changes, the lens
invaginates and subsequently induces the new surface ectoderm
to become the cornea. In the process, the cup of invaginating
tissue seals itself to become the eye. Retinal development
continues into early postnatal life as the neuroepithelium diffe-
rentiates, and the neurons migrate to their proper location
within the retina, extend processes, and form synaptic
connections.
The eye and other tissues express four primary families of
HSPG. The syndecans and glypicans associate with the cell
surface via transmembrane domains or glycosylphosphatidyli-
nositol (GPI)-linkages, respectively (Bernfield et al., 1999; Park
et al., 2000). Perlecan is an extracellular-matrix-associated
HSPG, and agrin is primarily found in the extracellular matrix,
though neurons also express a transmembrane isoform of the
protein (Burgess et al., 2002; Neumann et al., 2001).
Agrin is most studied for its role in the development of the
neuromuscular junction (NMJ) (Sanes and Lichtman, 1999), but
it is also abundantly expressed in the eye. This expression
suggests a possible function in eye development, although loss-
of-function mutations in agrin do not cause an eye phenotype
that is evident at birth, when the mice die from NMJ defects. In
this study, we report that overexpression of agrin caused a
variety of developmental eye defects, and that the penetrance of
the defects was agrin-dose dependent. In addition, the defects
were sensitive to genetic background and appeared in C57BL/
6J with high penetrance. This allowed a modifier locus causing
anophthalmia in the C57BL/6J background to be mapped to
Chromosome 2. This report is the first demonstration of an
overexpression phenotype for agrin, or any other HSPG, in the
vertebrate eye, and presents a model through which biochemical
and genetic interactions affecting neurodevelopment and
morphogenesis may be studied. The model is also consistent
with a role for HSPGs in multiple steps of eye development.
Materials and methods
Producing transgenic mice
A bacterial artificial chromosome (BAC) containing the entire Agrn gene, as
well as 7 kb of upstream DNA and 30 kb of downstream DNA, was used to
generate Agrn transgenic mice (BAC #19375, Genome Systems Inc, St. Louis,
MO). Agrn is the only annotated gene on this BAC. The coding sequence of
cyan fluorescent protein (CFP) was inserted into the last exon of Agrn, creating a
fusion of CFP onto the C-terminus of Agrn using bacterial recombineering
(Copeland et al., 2001; Lee et al., 2001). Two complementary primers, one
matching the last 60 base pairs of the agrin coding sequence plus the first 20 base
pairs of cyan fluorescent protein (CAG CTG CAT CTG CTG GAG GAC GCT
GTC ACC AAA CCA GAG CTA AGA CCC TGC CCC ACT CTC ATG GTG
AGC AAG GGC GAG GAG), and the other matching the first 60 base pairs of
agrin's 3′ untranslated region and 20 base pairs of plasmid vector sequence
(AAG TTTACAAAAATA GAAAATAAT TAC AGGAGGGAAGGT GGC
AGC TCT AGT GGC AGC TCA ACT CGA GCC CTTAAT TAA CCG GT),were used to amplify a CFP-loxP-FRT-TN5Neo-FRT cassette. The underlined
portions of the oligos match the 5′ end of CFP and the complementary strand
of the vector downstream of the Neo cassette. The loxP-frt-TN5Neo-frt
plasmid was generously provided by Dr. Francis Stewart and allows positive
selection with kanamycin in bacteria or neomycin in eukaryotic cells. This
cassette was introduced into the agrin BAC by bacterial recombineering in
EL250 Escherichia coli, and the selectable marker, TN5-Neo, was deleted
from the BAC construct by expression of FLP to mediate recombination at the
FRT sites.
Pronuclear microinjection was used to introduce the BACs into C57BL/6J
embryos. Three independent founders were produced with integrated BAC
constructs and expression levels of Agrn-CFP detectable by direct fluorescence.
These strains are designated C57BL/6J-Tg(MGS1-19375/CFP)2R9Rwb,
C57BL/6J-Tg(MGS1-19375/CFP)6R16Rwb and C57BL/6J-Tg(MGS1-19375/
CFP)4R24Rwb, and are referred to hereafter as AgrnCFP2R9, AgrnCFP6R16, and
AgrnCFP4R24. The unmodified BAC 19375 was also used to generate a
transgenic strain overexpressing Agrn without the CFP tag. This strain is
designated C57BL/6J-Tg(MGS1-19375)72Rwb and is hereafter referred to as
Agrn72.
Animal husbandry
Mice were used in accordance with protocols approved by the Animal Care
and Use Committee at The Jackson Laboratory. The Jackson Laboratory is
accredited by AAALAC. Animals were housed in PIV caging and given food
and water ad libitum.
Genetic rescue and Agrn dosage studies
For testing the functionality of the AgrnCFP transgenic strains and for
reducing the dosage of Agrn, we used a deletion allele of Agrn generated by
homologous recombination (Lin et al., 2001). This allele has the designation
B6.129-Agrntm4Jrs/Rwb and is hereafter referred to as AgrnDel. This strain
deletes exons 6 through 33 of the agrin gene. However, an N-terminal fragment
of agrin that is still produced and is recognized by antibodies such as GR14 (see
below). Importantly, the N-terminal fragment produced is not glycanated, as
predicted by sequence analysis searching for O-linked glycosylation consensus
sequences and by empirical tests. This characterization was performed in
collaboration with Dr. Jeffery H. Miner at Washington University and is
submitted for publication.
Transgene integration sites
Chromosomal Fluorescence In-Situ Hybridization (FISH) was performed
as previously described (Shopland et al., 2003). The Agrn BAC 19375 was
labeled as a probe to identify the transgenic insertion sites. Fine mapping of the
AgrnCFP2R9 insertion site was performed by probing interphase nuclei of
dispersed P5 hepatocytes with differentially labeled BACs, and assaying their
orientation relative to each other. For this experiment the Agrn BAC was used
in conjunction with two of the following BACs: RP23-114F11, RP24-263K11,
RP24-168N14, RP24-511J6 and RP24-178B17 (CHORI). The AgrnCFP2R9
transgene was found to have integrated in an intergenic region between RP24-
168N14 and RP24511J6 on Chromosome 8. No effect on expression of
flanking genes was observed, as assayed by real time PCR and northern blot
analysis.
Genotyping of transgenic mice
Transgenic mice were genotyped using primers to CFP, or to the pBelo-BAC
vector. To genotype the AgrnCFP transgenic strains, the primers XFP 5′ (ACC
ATG GTG AGC AAG GGC) and XFP 3′ (CTT TAC TTG TAC AGC TCG
TCC) were used. To genotype the Agrn72 strain, the BAC-vector primers 400F
(AGT GTC ACC TAA ATA GCT TG) and 900R (CAT GGG CAA ATA TTA
TAC GC) were used. Tail biopsies were digested overnight in 100 μl of 1 mg/ml
proteinase-K in 100 mM Tris pH 8.5, 10 mM EDTA, 200 mM NaCl buffer.
Samples were then boiled for 15 min to denature the DNA and inactivate the
proteinase-K. PCR was performed using master taq with the following program:
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72 °C for 2 min followed by a single 72 °C extension for 7 min (Eppendorf).
For Southern blot analysis, spleen was homogenized and digested with
proteinase-K as above with the addition of 0.1% SDS. Samples were then
phenol/chloroform extracted and precipitated with isopropanol. Genomic DNA
was resuspended in water and digested with NcoI. Digestion products were run
on a 0.8% agarose gel and transferred to Hybond membranes for blotting (GE
Healthcare Life Sciences). An 800 bp probe generated by PCR from exon 35 to
exon 36 of agrin was randomly primed using alpha-dCT32P and hybridized to
the membranes in Church buffer. High stringency washes were performed (final
conditions of 0.2× SSC, 0.1% SDS at 65 °C).
Immunohistochemistry
Tissue was fixed in 4% paraformaldehyde for 4 h, rinsed in PBS,
equilibrated overnight in PBS/30% sucrose for cryoprotection, and embedded
in OCT media. Ten-micron cryostat sections of eyes or embryos were used for
staining. Slides with sections were blocked in 1% BSA and 0.1% triton in PBS
for 30 min. Primary antibodies were incubated on sections overnight at 4 °C,
washed 4× 10 min in PBS and incubated with secondary antibodies for 1 h at
room temperature. Slides were washed 4× 15 min in PBS. The last wash
contained 1 μl of 1 mg/ml DAPI per 10 ml PBS. The following antibodies were
used: rabbit anti-GFP, 1:500 (Chemicon); rabbit anti-PAX2, 1:1000 (Chemicon);
mouse anti-PAX6, 1:25 NF clone 2H3, 1:1000; anti-SHH 1:50 (DSHB); rabbit
anti-SHH 1:500 (Santa Cruz Biotechnology) and goat anti-CHX10, 1:500 (Santa
Cruz Biotechnology). Sheep anti-agrin GR14 (1:800) was the generous gift of
Dr. J.H. Berden, Radboud University Nijmegen Medical Center, The Nether-
lands. The specificity of this anti-agrin antibody was established by staining the
kidney of a mouse strain completely lacking the isoform of agrin expressed in
kidney (Burgess et al., 2000) and observing that all GR14 immunoreactivity was
lost. Anti-mouse, -sheep, -rabbit and -goat secondary antibodies produced in
donkey and conjugated with either Cy3 (Jackson Immunoresearch) or alexa-488
(Molecular Probes) were used to detect the appropriate primary antibodies at a
dilution of 1:500.
Quantitative immunohistochemistry
Embryos were collected at E11.5, fixed for 2 h in 4% paraformaldehyde, and
sucrose cryoprotected overnight at 4 °C. Embryos were frozen in OCT
embedding media and cut in 10 μm sections, which were collected on slides
such that an embryo of every genotype was represented on a single slide. Slides
were blocked for 1 h in PBS supplemented with 3% normal horse serum and
incubated overnight at 4 °C with antibodies to tubulin and agrin (Sigma-
Aldrich). Primary antibodies were detected using a Cy3 labeled donkey anti-
sheep antibody and an alexa-488 labeled goat anti-mouse IgG1 antibody
(Jackson Immuno-Research and Molecular Probes, respectively). Slides were
washed four times for 10 min in PBS and coverslipped. Images were acquired
using a Leica SP5 confocal microscope with the same microscope parameters
for all embryos. Agrin staining in the inner limiting membrane of the embryonic
eye was imaged and normalized against tubulin staining in paraocular nerves.
Three embryos (for a total of six eyes) were imaged for each genotype.
Fluorescence intensity in the red and green channels was determined using the
ImageJ RGB Measure Plugin.
Western blot analysis
Western blot analysis was performed on E11.5 embryo heads. 60 μg total
protein was loaded in each lane. Blots were transferred to PVDFmembranes and
blocked in TBST (0.05% Tween) and 5% non-fat dry milk. Blots were probed
using mouse monoclonal antibodies to GFP at a dilution of 1:4,000 (Invitrogen,
clone 3E6) overnight at 4 °C followed by two 10 min washes at room
temperature. Primary antibodies were detected using HRP labeled secondary
antibodies at a dilution of 1:8,000, which were incubated for 1 h at room
temperature (Perkin-Elmer, goat anti-mouse). All antibodies were diluted in TBS
0.05% Tween and 5% non-fat dry milk. Blots were stripped and reprobed with an
antibody to MAP2 at a dilution of 1:2,000, which was used as a loading control
(Chemicon). Four embryos of each genotype were examined. Densitometry wasperformed using ImageJ, and the ratio of anti-GFP to anti-MAP2was determined
for each lane. The mean ratio of CFP2R9, the highest expressing line, to MAP2
was chosen as 100%, and other ratios were expressed as a percentage of that
value. Protein homogenates from the CFP2R9 strain were also treated with
heparatinase (EC#4.2.2.8) or chondroitinase-ABC (EC#4.2.2.4) according to
the manufacturers protocols (Seigaku), and blotted as described.
Transcript analysis
Isolation of RNA was performed using Trizol reagent according to
manufacturer's instructions (Invitrogen). Messenger RNA was isolated by
passage of total RNA over an oligo-dT cellulose column (Ambion). Two
micrograms of mRNA from transgenic and wild-type mice was used per lane for
northern blot analysis. The agrin probe was amplified by PCR from exon 21 to
exon 25. First-strand cDNA was produced using a Superscript III first strand
synthesis kit (Invitrogen) following the manufacturer's instructions with 5 μg of
total RNA and a mix of dT and random hexamer primers used in each reaction.
Quantitative real-time PCR was performed using the primers agrin F (GGT GCT
GTG GAT TGG AAA GGT) and agrin R (TGC TGC GCT CCA CTG TGA) or
beta-actin F (CAA CCG TGA AAA GAT GAC CCA GAT C) and beta-actin R
(GAATTG AAT GTA GTT TCATGG ATG CCA C), with sybr green (ABI) for
detection of amplification products.
Quantitative Trait Locus (QTL) analysis and mapping cross
Female mice from a BALB/cJ by C57BL/6J mating (CB6F1/J) were crossed
to male AgrnCFP2R9 transgenic mice. At P28 mice were genotyped and eyes
were enucleated and examined using a dissecting microscope. DNA was
collected and purified from 100 AgrnCFP2R9 transgenic mice with various
developmental defects. A genome-wide linkage analysis scan was performed by
typing 140 strain specific single nucleotide polymorphisms (SNPs) spaced
approximately every 10 mb along the chromosomes (K Bioscience). To establish
significance thresholds for QTL testing, this data was used to simulate a whole-
genome scan, performed at 5-cM spacing using 64 imputations and 100
permutations. These thresholds for the 1%, 5%, 10% and 63% significance
levels are represented by the horizontal lines from greatest to smallest in each
plot. QTL above the 1% threshold are considered strong QTL, while those above
63% are considered suggestive QTL (Doerge and Churchill, 1996; Sen and
Churchill, 2001).
Results
Agrin transgenic mouse strains
Four strains of transgenic mice were generated by pronuclear
injection of a BAC containing the Agrn gene into C57BL/6J
embryos, as described in Materials and methods. Three of the
four strains were made using a modified Agrn BAC producing
enhanced cyan fluorescent protein (CFP) fused onto the C-
terminus of agrin (AgrnCFP, Fig. 1A). The fourth transgenic
strain was made using the same agrin-containing BAC without
CFP modification.
The deletion of agrin causes neonatal lethality, due to a failure
of neuromuscular junction (NMJ) formation and maintenance.
The transgenic AgrnCFP strains CFP2R9 and CFP6R16 were
capable of rescuing the lethality associated with deletion of
Agrn, indicating that the transgenic protein is functional even
with the CFP fusion. Staining NMJs with antibodies against
neurofilament to visualize the nerve, and with rhodamine-
conjugated α-bungaortoxin to visualize postsynaptic acetylcho-
line receptors, revealed no morphological differences between
transgene-rescued and wild-type neuromuscular junctions (Figs.
1B, C, N=3). The transgenic agrin-CFP protein was detectable
Fig. 1. Agrin transgenic mice. A) Agrin is a 40-exon gene spanning approximately 40 kb of genomic DNA. The agrin protein is almost 2000 amino acids long, with
either a transmembrane N-terminus (SN-agrin) or an N-terminus with a signal peptide for secretion (LN-agrin). In the N-terminal half of the protein, there are nine-
follistatin repeats (F), a laminin-like domain (L), two serine/threonine-rich regions (ST), and an SEA domain. In the C-terminal half, there are four EGF-like repeats
(EGF) and three laminin-type globular domains (G). There are also at least three sites of alternative splicing (X, Y, Z). The sites of glycosaminoglycan (GAG) addition
are in the N-terminal half of agrin. The agrin transgene construct was a BAC containing the entire agrin gene, in some cases modified to fuse cyan fluorescent protein
(CFP) onto the C-terminus of agrin. B) The AgrnCFP transgene was functional and rescued the neonatal lethality caused by the deletion of agrin by homologous
recombination. Mice homozygous for an agrin deletion, but carrying the transgene, had neuromuscular junctions (NMJs) that were indistinguishable from controls (C).
The nerve, stained for neurofilament (green) overlapped the postsynaptic acetylcholine receptors labeled with α-bungarotoxin (red). The NMJs shown were from P12
mice. (D) The genotypes of mice rescued by the AgrnCFP2R9 and AgrnCFP6R16 transgenic strains were confirmed by Southern blotting. Digestion of genomic DNAwith
NcoI yielded the anticipated 2 kb band in the null allele, a 5 kb band in the wild-type allele, and a 6 kb band in the AgrnCFP transgene (caused by the CFP insertion).
Lane 1 AgrnDel/Del rescued by the AgrnCFP2R9 insertion, compared to an AgrnDel/+littermate (lane 2). Lane 3 AgrnDel/Del rescued by the AgrnCFP6R16 transgene,
compared to an AgrnDel/+ (lane 4). Lane 5 was a wild-type control. Notice the higher copy number of the AgrnCFP insertion in the 2R9 strain (dark 6 kb band). (E)
Northern blotting confirmed that the only agrin transcripts generated in the rescued mice were the AgrnCFP from the transgene. The transgenic transcript was shifted by
1 kb by the CFP insertion. The same blots were hybridized with probes against Agrin, CFP, and β-actin as a loading control. Densitometry using a phosphorimager
indicated that agrin was overexpressed approximately 2.5-fold in the 2R9 strain (shown in (E) at P12). F) The agrin-CFP protein was detectable by Western blotting
using an anti-GFP antibody. The antibody did not recognize protein from non-transgenic mice (lane1), but recognized a high-molecular-weight smear in the AgrnCFP
transgenic strains (arrowhead at 250 kDa). A smaller degradation or cleavage product was also evident, as previously reported for the endogenous protein. Relative
expression levels of the AgrnCFP strains are shown, with MAP2 as a loading control shown below. G) The protein smear was reduced to a sharp band by treatment with
heparatinase, and only partially affected by treatment with Chondroitinase ABC, consistent with the transgenic protein also being a heparansulfate proteoglycan.
168 P.G. Fuerst et al. / Developmental Biology 303 (2007) 165–180at the NMJ using antibodies against GFP, and this staining was
specific, as no anti-GFP immunoreactivity was seen in non-
transgenic mice (not shown). Genotypes of the rescued mice
were confirmed by Southern blotting (Fig. 1D). Agrn mRNAwas analyzed by reverse-transcriptase PCR (RT-PCR) and
northern blot analysis, which confirmed that the only Agrn
expressed in the rescued mice was derived from the transgene
(Fig. 1E). Densitometry of the northern blot compared to a β-
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agrin transcripts in theCFP2R9 strain. Agrin mRNA and protein
expression levels were further examined by quantitative real-
time PCR (qRT-PCR), quantitative immunofluorescence, and
western blotting. The four transgenic lines expressed transgenic
Agrn mRNA at levels 2.7, 2.4, 1.6 and 1.4 times higher than the
endogenous gene by qRT-PCR and agrin transgenic protein at
3.3, 2.3, 1.2 and 0.8 times higher than endogenous protein levels
by quantitative immunofluorescence (Table 1, AgrnCFP2R9,
Agrn72, AgrnCFP6R16, AgrnCFP2R24 values respectively). The
transgenic protein is detectable on a western blot using anti-GFP
antibodies to recognize the C-terminal CFP fusion (Fig. 1F).
Western blot analysis also showed protein levels of Agrn-
CFP2R9>Agrn-CFP6R16>Agrn-CFP4R24 (Table 1). The
agrin-CFP protein ran as a high molecular-weight smear,
suggesting a glycoprotein. The smear was reduced to a band
of approximately 275 kDa with heparitinase treatment and was
less altered by digestion with chondroitinase ABC, consistent
with the transgenic agrin-CFP being primarily a heparan sulfate
proteoglycan (Fig. 1G).
Agrin overexpression disrupts eye development
The overexpression of agrin caused a phenotype specific to
the eye. No overt neurological phenotypes such as tremor,
seizures, or ataxia and no histological changes in the anatomy ofTable 1
Agrin transgene expression levels
Strain Agrn vs. WT
qRTPCR
Total agrin
vs. WT QIF
Agrin-CFP vs.
AgrnCFP2R9 WBA
Percent
dysgenic mice a
AgrnCFP2R9 370±7.4% 434±78% 100±11% 95% (86/95)
AgrnCFP6R16 260±18.2% 217±26% 44±8.7% 1% (1/88) b
AgrnCFP4R24 240±7.2% 178±56% 25±5% 6% (3/54)
Agrn72 340±17% 330±41% NA 70% (42/60)
Wild-type c 100±4% 100±17% NA 2% (2/106)
Levels of Agrn mRNA and agrin protein in transgenic mice. Four Agrn
transgenic lines were analyzed for their agrin expression compared to the
endogenous gene. Real time PCR was used to compare the level of transgenic
Agrn mRNA expression to wild type littermates using β-actin as an internal
control. Total agrin protein levels were determined and compared to wild type
littermates by quantitative immunoflourescence, using anti-tubulin staining as a
control. Agrin-CFP levels were measured in transgenic mice by western blot
analysis, using MAP2 as a loading control. Levels of transgenic Agrn expression
and protein were found to correlate with the penetrance of ocular dysgenesis. The
AgrnCFP2R9 line expressed the most Agrn and had the highest incidence of
defects, followed by the Agrn72 line. The AgrnCFP6R16 line initially had an
incidence of ocular dysgenesis of approximately 30% (11 of 31 mice), but after
breeding, the incidence of dysgenesis approached the spontaneous level
observed in wild-type C57BL/6J mice. The AgrnCFP4R24 line expressed the
lowest levels of Agrn and had an incidence of dysgenesis similar to wild-type
C57BL/6J mice. The number of dysgenic mice over the total number of mice of
each genotype analyzed is given.
qRT-PCR, Real-time PCR; QIF, Quantitative immunofluorescence; WBA,
Western blot analysis.
a Mice were considered dysgenic if either of both eyes were developmentally
abnormal based upon clinical examination.
b Eleven of thirty-one AgrnCFP6R16 mice were dysgenic in the first generation,
but rates fell to control values in subsequent generations as reported above.
c Wild-type mice are non-transgenic littermates of AgrnCFP2R9.agrin-rich tissues such as brain, muscle, or kidney were
observed (not shown). Furthermore, no changes were observed
in neuromuscular junction morphology, the site at which agrin's
function is best documented. Indeed the original AgrnCFP2R9
transgenic founder survived over 2 years. However, mice with
high transgene expression levels had ocular dysgenesis with
nearly complete penetrance. The two transgenic strains with
highest Agrn expression had rates of ocular dysgenesis of 95%
and 70% respectively (CFP2R9 and 72). The lines with lower
transgenic expression of AgrnCFP (CFP6R16 and CFP4R24)
had an incidence of ocular dysgenesis similar to the sponta-
neous rate of occurrence in wild-type C57BL/6J mice (Table 1).
The transgene insertions that caused eye defects with high
penetrance are independent insertions. The genomic integration
sites of the BACs were determined by FISH, and they were found
to have integrated on different chromosomes (not shown),
indicating the phenotype is not caused by a mutation created by
the transgene insertion. In addition, one strain contains the CFP
fusion (AgrnCFP2R9) and the other is the unmodified agrin BAC
(Agrn72), indicating that the eye defects are not caused by the CFP.
The ocular dysgenesis correlated with the amount of Agrn
expressed (Table 1). However, the phenotype could also be
caused by the parallel expression of some other factor carried on
the BAC. To test this, the level of Agrn expression was spe-
cifically decreased by crossing the high-expressing AgrnCFP2R9
and Agrn72 transgenic strains to an isogenic strain carrying an
Agrn deletion (AgrnDel, Chromosome 4) (Lin et al., 2001).
Decreasing the dosage of Agrn by generating AgrnDel/+or
AgrnDel/Del mice in an AgrnCFP2R9 transgenic background re-
duced the incidence of dysgenesis to 56% of the mice hetero-
zygous for the deletion, or 45% in mice homozygous for the
deletion compared to 92% in wild-type littermates (Table 2).
Similarly Agrn72 in an AgrnDel/+ background also reduced the
incidence of eye defects to 56% from 73% in littermates. In
AgrnDel/Del mice not carrying the AgrnCFP2R9 transgene, exam-
ined at E18.5, 10 out of 11 examined had normal eyes, indicating
that the ocular dysgenesis is not a part of the agrin loss-of-
function phenotype (Table 2).
The reduction in agrin protein in the agrnDel allele was
quantified by immunofluorescence. Fluorescence intensities in
AgrnDel/Del mice were 64±14% that seen in wild-type mice, and
the AgrnCFP2R9; AgrinDel/Del mice were 318±28%, consistent
with the reduced incidence of eye defects in AgrnCFP2R9 mice
mated to the AgrnDel allele. The AgrnDel allele expressed an N-
terminal agrin fragment recognized by the antibody, although it
is not glycanated and has no known activity (see Materials and
methods). Thus, the decrease in penetrance of eye defects in
AgrnDel backgrounds may be due to an even greater effective
decrease in agrin protein levels than the staining indicates.
The ocular phenotypes observed in mice overexpressing
Agrn are similar to those observed at a low spontaneous level in
C57BL/6J and related Black strains such as C57BL/10, C58BL,
and C57BL/Kahles. These defects range from anophthalmia to
corneal–lenticular adhesions (Smith et al., 1994). The incidence
and types of dysgenesis in mice carrying the highest-expressing
transgene (AgrnCFP2R9) was determined during embryonic
development and in adults (Table 3). Most of the observed
Table 2
Effect of Agrn dosage on the penetrance of eye defects
Agrn genotype a Transgene Percent dysgenic b
Del/Del Non-Tg 9% (1/11) c
Del/+ Non-Tg 3% (1/29)
+/+ Non-Tg 0% (0/15)
Del/Del AgrnCFP2R9 45% (4/11)
Del/+ AgrnCFP2R9 56% (20/36)
+/+ AgrnCFP2R9 92% (11/12)
Del/+ Agrn72 56% (10/18) c
+/+ Agrn72 73% (17/23) c
Agrn dosage effect. Agrn dosage was reduced by introducing AgrnDel/+or
AgrnDel/Del alleles into the AgrnCFP2R9 or Agrn72 backgrounds. Replacing a
single wild-type allele in the AgrnCFP2R9 line with the deletion reduced the
incidence of dysgenesis from 92% to 56%, while being homozygous for the
deletion reduced the incidence of defects to 45%. Agrn72 mice carrying a single
wild type allele of Agrn had a 17% decrease in the incidence of ocular
dysgenesis. Littermate controls that did not carry an Agrn transgene had a very
low incidence of dysgenesis; 2 mice out of 55 not carrying an Agrn transgene
had malformed eyes, consistent with the background incidence of these defects.
Importantly, the AgrnDel/Delmice did not have dysgenic eyes, consistent with the
phenotype not being part of the Agrn loss-of-function phenotype.
a The agrn genotype at the endogenous Chromosome 4 locus.
b A mouse was scored as dysgenic if one or both eyes had any developmental
phenotype by clinical and histological examination.
c AgrnDel/Del; Non-Tg mice and Agrn72 were collected at E18.5.
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chamber structures, 2) pigmented persistent hyperplastic pri-
mary vitreous (PHPV) associated with a failure to close the
fetal fissure, and 3) coloboma and misdifferentiation of the
optic stalk. Examples of these phenotypes are shown in
Supplemental Fig. 1. The first two categories of phenotype are
spontaneous defects normally observed at low frequency in
C57BL/6J and related strains, while the third has not been
described in C57BL/6.
Localization of transgenic and wild-type agrin in the eye
To determine whether the transgenic agrin-CFP protein has
wild-type localization or is ectopically expressed within the eye,
transgenic and wild-type eye sections were stained using
antibodies directed against agrin (GR14) to detect endogenous
and transgenic agrin (Raats et al., 1998), and against GFP,
which cross reacts with CFP, to detect transgenic agrin-CFP.Table 3
Prevalence of dysgenesis in AgrnCFP2R9 transgenic mice
Dysgenesis a E9.5 E10.5 E12.
PHPV NAb NA NA
Iridocorneal adhesion NA NA NA
Corneal–lenticular adhesions NA NA 80%
Iris/fetal fissure coloboma c NA NA 40%
Microphthalmia NA/ND NA/ND NA/N
Anophthalmia NA/ND NA/ND 13%
Optic cup orientation (0/11) 72% (8/11) NA
Prevalence of dysgenesis in AgrnCFP2R9 transgenic mice. Dysgenesis was evaluated
were scored; numbers reported represent mice. A given mouse could fall into multi
a Numbers represent mice. Both eyes of a given mouse were evaluated.
b ND=Not determined, NA=Not applicable.
c Includes coloboma and misdifferentiation of the optic stalk.Distribution of agrin in sections of wild-type eyes was
identical to the distribution of agrin-CFP in transgenic eyes,
indicating that transgenic agrin-CFP is not ectopically localized
in the eye (Figs. 2A–D, data not shown). Agrin-CFP in the
retina was localized to the internal limiting membrane, to cells
at the boundary of the inner plexiform layer, to the inner nuclear
layer, and to the outer plexiform layer (Figs. 2B, D). Double
labeling experiments were performed to identify the agrin-CFP-
positive cell populations. No significant co-localization of
agrin-CFP with PAX6 (a marker of amacrine, ganglion and
horizontal cells) or with vimentin (a marker of Mueller glia) was
observed. However, agrin-CFP did co-localize with laminin, a
marker of endothelial cells, which identified these cells as part
of the retinal vasculature (Fig. 2E, data not shown). Outside the
neural retina, agrin-CFP was localized to the basal lamina of
several distinct structures in the adult eye, including retinal
vasculature, the internal limiting membrane, the lens capsule,
the ciliary body and the iris, as well as Descemet's membrane
and Bowman's layer of the cornea (Figs. 2F–H). In the optic
nerve, agrin-CFP was localized to the outer sheath of the nerve
and was not detectable on axons in adult samples (Fig. 2I).
In the developing eye, agrin-CFP was localized along the
neural ectoderm and surface ectoderm at E9.5, the outer face of
the optic cup, the interior surface of the optic stalk and the
interior invaginating lens capsule at E10.5 and E12, and the
hyaloid vessels at E14 (Figs. 3A–D). As in adult mice,
transgenic agrin-CFP distribution was identical to that of agrin
in the wild-type eye, as determined using the GR14 antibody to
agrin (Figs. 3E, F). Since localization of wild-type and transgenic
agrin overlapped completely, detection of transgenic agrin in the
rest of this study was performed using antibodies to GFP.
Agrin-CFP localizes to dysgenic structures
To assess whether the effect of agrin overexpression on eye
development could be a direct consequence of the presence of
the transgenic protein, the localization of agrin-CFP was
assayed in eye structures at times corresponding to the initiation
of dysgenesis. Direct effects of agrin-CFP could include the
altered presentation of growth factors or changes in cell
adhesion or migration that are normally mediated by the ECM
within the eye. Indirect effects could include factors that5 E14–16 P0 P21
NA 59% (10/17) 51% (109/214)
NA 12% (2/17) 11% (24/214)
(12/15) 70% (7/10) 82% (14/17) 75% (161/214)
(6/15) 34% (21/62) 18% (3/17) 15% (32/214)
D NA/ND NA/ND 3% (7/214)
(2/15) 3% (2/62) 6% (1/17) 37% (79/214)
NA NA NA
at different developmental stages in transgenic mice. Both eyes of each mouse
ple categories if different phenotypes were present in each eye.
Fig. 2. Distribution of agrin and agrin-CFP in the adult mouse eye. (A) Cross sections of wild type retinas stained with anti-agrin antibodies (GR14, red) revealed agrin
to be localized to cells on the edges of the inner nuclear layer (INL) and outer plexiform layer (OPL), which were identified as blood vessels, and along the internal
limiting membrane (ILM). The photoreceptors of the outer nuclear layer (ONL) were not labeled. (B) Cross sections of AgrnCFP6R16 retinas labeled using an anti-GFP
antibody to recognize the transgenic protein (red), showed agrin-CFP localization to be identical to anti-agrin on wild-type sections. (C) Transverse sections of wild-
type eyes stained with anti-GFP antibodies showed no staining, establishing that the antibody is specific for the transgenic agrin-CFP protein. (D) Sections of
transgenic retinas stained with the GR14 anti-agrin (red) revealed the same localization. (E) Transverse sections of transgenic retinas probed with antibodies to GFP
(red) and PAX6 (green) revealed that agrin-CFP does not co-localize with PAX6. (F) In the cornea, agrin-CFP is localized to Descemet's membrane (DM) and
Bowman's layer (BL). (G, H) In the anterior chamber of the eye, agrin-CFP is localized to the iris (I), ciliary bodies (CB) and lens capsule (LC). (I) Sections of optic
nerve from AgrnCFP6R16 mice showed agrin-CFP localization to the outer sheath (OS) of the nerve, which is continuous with the blood–brain barrier. Retinal sections
are oriented with the retinal ganglion layer (RGL) up. All sections are counter-stained with DAPI (blue) to visualize nuclei. The measurement bar located in the lower
right panel is equivalent to 75 μm in A, B, C, F and H, 225 μm in D and E, and 37.5 μm in G and I.
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C57BL/6J to develop abnormal eyes, as seen in fetal alcohol
exposure (Sulik et al., 1981).
Agrin-CFP was indeed present in structures that become
malformed, immediately preceding and following the initiation
of dysgenesis. The lens stalk connecting the developing lens to
the overlying surface ectoderm typically is lost through anapoptotic mechanism by E12 in wild-type mice. Agrin-CFP is
localized to the basal lamina of the lens stalk in E11.5
embryonic samples. In E14 samples, agrin-CFP was in the fetal
fissure (Fig. 4B), which closes by E12 in wild-type embryos,
but frequently persisted in the transgenic eyes. The open fissure
may contribute to the infilitration of fibrovascular tissue
observed later. Coloboma and misdifferentiation of the optic
Fig. 3. Agrin and agrin-CFP localization in the developing eye. The presence of agrin in the developing eye was assayed at four times relevant to the onset of
developmental defects observed in dysgenic eyes. (A) In E9.5 AgrnCFP6R16 embryos stained with antibodies to GFP, agrin-CFP is localized to the ECM separating the
neural and surface ectoderm (NE and SE). (B) In E10.5 transgenic embryos, agrin-CFP is localized to the ECM of the interior optic cup (OC) and surrounding the
invaginating lens (L), as well as along the exterior optic stalk (OS). (C) In E12 transgenic embryos, agrin-CFP is present in the ECM of the optic cup (OC), lens capsule
(L) and inner and outer optic stalk (OS). (D) In E14 transgenic embryos agrin-CFP is localized to the vitreous (V) and internal limiting membrane (ILM) of the retina
(R). Sections of wild-type eyes at E12 (E) and E14 (F) were stained with an anti-agrin antibody (GR14, red). The distribution of agrin in the wild-type developing eye is
the same as the distribution of transgenic agrin-CFP in AgrnCFP6R16 transgenic mice. All sections are counterstained with DAPI (blue) to visualize the nuclei. The
measurement bar located in the lower right panel is equivalent to 165 μm in A, 210 μm in B and 250 μm in C–F.
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entire dorsal optic nerve differentiates as retina in affected
embryos, as determined by histology and the expression of the
retina-specific marker CHX10 (Figs. 4C, D). Agrin-CFP is
abundantly localized to the surface of the misdifferentiated optic
nerve. Maintenance of the boundary between the optic cup and
the optic stalk is mediated by restriction of Pax6 expression to
the optic cup, while PAX2 is found in the developing nerve in
wild-type embryos. In dysgenic AgrnCFP2R9 eyes, PAX6 islocalized to the misdifferentiated dorsal optic nerve, while
PAX2 is localized to the ventral optic nerve (Fig. 4E). In
neonatal mice, an acellular ECM, containing agrin-CFP and
dystroglycan, connected the lens and cornea of the transgenic
eye (Fig. 4F). Agrin-CFP was also localized to the hyaloid
vessels, which adhere to the surface of the retina (Fig. 4G).
After eye opening in mice with a fusion of either the lens or the
iris with the cornea, agrin-CFP was found in endothelial tissue
bridging adhesions (Figs. 4H, I).
Fig. 4. Agrin-CFP localization in the dysgenic eye. (A) In E11.5 AgrnCFP2R9 eyes stained with antibodies to GFP (red), agrin-CFP is localized throughout the lens stalk
(LS), as well as along the basal lamina of the surface epithelium and lens, and the internal limiting membrane (ILM) of the optic cup (OC). (B) Transverse sections
through the ventral optic cup of E14 AgrnCFP2R9 eye revealed agrin-CFP to be localized to the persistent fetal fissure (FF). (C) Transverse sections through E16
AgrnCFP2R9 embryos stained with hematoxylin and eosin revealed misdifferentiation of retinal tissue along the length of the optic nerve. The retina (R) formed in place
of the dorsal portion of the optic nerve (ON), and is continuous with the forebrain (FB). (D) E15 AgrnCFP2R9 optic nerve sections were stained with antibodies to GFP,
to detect agrin-CFP (green), and CHX10 (red), a marker of retinal differentiation. The retinal pigment epithelium, visualized with brightfield microscopy, is marked on
the image (arrow). CHX10 labeled the misdifferentiated tissue, and agrin-CFP is localized to the ECM surrounding the optic nerve. (E) Sagittal sections of E15
AgrnCFP2R9 optic nerves were stained with antibodies to PAX6 (green) and PAX2 (red), PAX6 localized to the dorsal half of the optic nerve, while PAX2 localized to
the ventral half. The retinal pigment epithelium is again marked (arrow). (F) In P0 AgrnCFP2R9 eyes double-labeled with anti-GFP to detect agrin-CFP (red) and
dystroglycan (green), agrin-CFP co-localizes with dystroglycan in acellular ECM connecting the lens and cornea. (G) In P0 AgrnCFP2R9 eyes with infiltration of
fibrovascular tissue, agrin-CFP localized to hyaloid vessels (V) adhering to folds of the retina (R). (H) In P20 AgrnCFP2R9 eyes with lens–cornea fusions, agrin-CFP
localized to the basal lamina of the cornea (arrow heads) and to tissue connecting the lens and cornea (arrow). (I) In P20 AgrnCFP2R9 eyes with irideocorneal fusion,
agrin-CFP is localized to the points of adhesion between the iris and cornea (arrowhead). The measurement bar located in the lower right panel is equivalent to 90 μm
in A, 250 μm in B, 1.1 mm in C, 220 μm in D and E, 105 μm in F, 180 μm in G, 75 μm in H, and 35 μm in I.
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To further define the developmental pathways perturbed by
agrin overexpression, the PAX2/PAX6 boundary defects (Figs.
4C–E) were further examined. The Pax2 and Pax6 expressiondomains underlie optic nerve and retinal differentiation
respectively, and defects in the boundary between the domains
cause optic nerve misdifferentiation in other models (Mui et al.,
2005; Take-uchi et al., 2003). Immunohistochemistry was
performed on sections of wild-type and transgenic mice at two
174 P.G. Fuerst et al. / Developmental Biology 303 (2007) 165–180embryonic stages to identify the age at which the PAX2/PAX6
boundary became abnormal. The developing eyes of trans-
genic and wild-type mice had similar patterns of PAX2 and
PAX6 localization at E12, despite the morphological abnor-
mality of transgenic eyes at this point (Figs. 5A–C, N=5).
However, by E14, PAX6 had expanded into the optic nerve of
AgrnCFP2R9 mice, particularly in the dorsal portion of the
nerve (N=3) (Figs. 5D–F).
Sonic hedgehog (SHH), which maintains repression of Pax6
in the optic stalk, was monitored at E11.5 in the midbrain and at
E12.5 and E14 at the optic disk (N=2, 5 and 3 respectively), to
assess whether a change in the distribution of this molecule
correlated with expansion of the PAX6 domain in the Agrn-
optic nerve. The SHH staining pattern and intensity was similar
in transgenic and control embryos in the midbrain at E11.5, or at
the posterior optic cup at E12.5 (Fig. 6A–D). However, by E14,
widely varying staining of SHH that was less intense than wild
type was observed in AgrnCFP2R9 mice (Figs. 6E, F).
Retinal ganglion cells in AgrnCFP2R9 retinas, identified by
expression of BRN3b (POU4f2), were apparent by E13, indi-
cating that a decrease in SHH levels in the developing optic
nerve was not caused by a failure of retinal ganglion cell neuro-
genesis (data not shown). However, the lower levels of SHH
could have been from a decrease in the number of axons
navigating down the developing nerve. To assess the number of
RGC axons associated with the optic nerve, cross sections wereFig. 5. PAX2 and PAX6 localization in AgrnCFP2R9 and wild-type eyes during develo
(red) and PAX6 (green). Mildly affected and severely affected examples of AgrnCFP
wild-type embryos at developmental day 12.5, PAX6 is localized to the peripheral op
In AgrnCFP2R9 eyes at developmental day E12.5, PAX2 and PAX6 localization is sim
localized to the posterior margins of the optic cup and optic stalk, regardless of the deg
localized to the optic nerve in wild-type eyes. (E) In mildly dysgenic AgrnCFP2R9 e
limited to the optic cup, and PAX2 limited to the optic nerve. (F) However, in seve
expanded medially along the dorsal optic nerve, while PAX2 localized to the ventral m
panel is equivalent to 215 μm in A–C and 415 μm in D–F.stained with an antibody to neurofilament (NF), and PAX2.
Compared to wild type, the optic nerve of transgenic mice with
optic nerve colobomas had markedly less neurofilament
immunoreactivity along the ventral portion of the optic nerve,
and the cross-sectional area was considerably larger than in wild
type, because of the coloboma (Figs. 6G–J, N3 transgenic and
WT).
Distinct loci underlie C57BL/6J sensitivity to Agrn
overexpression
The ocular dysgenesis observed in Agrn overexpressing
C57BL/6J mice closely resembled the low incidence of defects
that occur spontaneously in this inbred strain, suggesting that
C57BL/6J is sensitized to the defects induced by Agrn
overexpression. Ocular dysgenesis was observed in F1 Agrn-
mice derived from crosses to closely related strains (C57BL/
10J, C57BL/6J, C57BR/cdJ and C57BL/6ByJ), but was not
observed in F1 mice from crosses to more distantly related
inbred strains, including C3H/HeJ, BALB/cJ, DBA/2J and SJL/
J. Backcrossing the latter F1 mice to C57BL/6J, or intercrossing
the F1 progeny, resulted in varying degrees and penetrance of
ocular defects, indicating the presence of recessive sensitivity
loci in C57BL/6J and possibly dominant repressors in the non-
C57BL/6J strains. Expression levels of AgrnCFP2R9 in different
genetic backgrounds did not change, as measured by qRT-PCR,pment. Embryonic eyes at E12.5 and E14 were labeled with antibodies to PAX2
2R9 eyes are shown in the middle column and right column respectively. (A) In
tic cup, while PAX2 is limited to the posterior margin of the optic cup. (B and C)
ilar to that of the wild-type eye; PAX6 is limited to the optic cup and PAX2 is
ree of dysgenesis. (D) At E14, PAX6 is localized to the optic cup, while PAX2 is
yes at E14, PAX6 and PAX2 localization was similar to wild-type, with PAX6
rely dysgenic AgrnCFP2R9 eyes with optic nerve colobomas, PAX6 localization
argin of the medial optic nerve. The measurement bar located in the lower right
Fig. 6. SHH and optic nerve development in AgrnCFP2R9mice. The schematics in the left column represent the planes of section and regions of interest for each pair of
images, shown in relation to the developing eyes and optic nerve. (A and B) Transverse sections of wild-type and AgrnCFP2R9 E11 embryos stained with antibodies to
SHH (green) revealed a similar midline and parasagittal staining pattern in the telencephalon. (C and D) Transverse sections of E12.5 embryos stained with antibodies
to SHH (red) showed a similar staining intensity in AgrnCFP2R9 mice compared to controls. (E and F) Wild-type and AgrnCFP2R9 E14 embryos sectioned at the optic
disc and double-labeled with antibodies to SHH (green) and neurofilament (NF, red) showed varying levels of SHH in AgrnCF2R9Pmice, ranging from nearly wild type
to vastly reduced (an intermediate example is shown in F). (G–J) Sagittal sections at the optic disc (G, H) or in the developing optic nerve (I, J) from E12.5 embryos
were stained with antibodies to NF (green) and PAX2 (red) to visualize the retinal ganglion cell axons and the cells of the optic stalk, respectively. NF staining was
reduced in the AgrnCFP2R9 transgenic optic nerve compared to wild-type. The cross-section of the optic nerve of AgrnCFP2R9 embryos was also much larger compared
to wild type controls, reflecting the failure of the optic stalk to fuse. The measurement bar located in the lower right panel is equivalent to 280 μm in A and B, 98 μm in
C and D, 95 μm in E and F, 70 μm in G and H and 50 μm in I and J.
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therefore could not explain the strain-specificity of dysgenesis
(not shown).A genetic mapping cross was performed to identify
chromosomal regions associated with ocular dysgenesis in
C57BL/6J mice overexpressing AgrnCFP2R9, and linkage
176 P.G. Fuerst et al. / Developmental Biology 303 (2007) 165–180analysis was performed. Treating all forms of dysgenesis as a
single phenotype with varying severity did not yield any
significant linkage in whole-genome scans (Fig. 7A). A
suggestive locus was observed on Chromosome 13, and nearly
suggestive loci were observed linked to Chromosomes 2, 4 and
11. If the model of a single eye phenotype with varying severityFig. 7. QTLmaps of C57BL/6J loci associated with ocular dysgenesis. A plot of the lo
observed levels in dysgenic mice. Chromosome numbers are plotted along the X-axis
Modeling the various types of ocular dysgenesis observed in AgrnCFP2R9 mice as a co
Chromosome 13. The ocular defects observed in AgrnCFP2R9 mice were therefore also
anophthalmia and microphthalmia, was detected in the middle of Chromosome 2, ce
fissure, was detected on Chromosome 4. (D) A suggestive QTL, correlating with corn
(E) A suggestive QTL, correlating iridocorneal adhesions, was detected on Chrom
Chromosome 13.in C57BL/6 mice overexpressing Agrn is accurate, then the
phenotype is the result of multiple interacting genomic loci,
each of which has a weak effect on the phenotype.
To model an alternative hypothesis, in which the dysgenesis
observed in AgrnCFP2R9 mice is a group of distinct phenotypes
affecting eye development at discrete steps, the mice genotypedg of odds (lod) that a given chromosomal location would segregate in the cross at
with the centromeric end to the left. The log of odds is plotted on the Y-axis. (A)
ntinuous spectrum of a single phenotype identified a single suggestive locus on
modeled as distinct phenotypes. (B) A highly significant QTL, correlating with
ntered at 35 cM. (C) A suggestive QTL, correlating with coloboma of the fetal
eal lenticular adhesions, was detected on the proximal portion of Chromosome 2.
osome 12. (F) A suggestive QTL, correlating with PHPV, was detected on
Table 4
AgrnCFP associated C57/BL/6J eye development QTLs
Phenotype Chromosome cM position # Mice LOD % Dysgenic a
Anophthalmia/
microphthalmia
2 35 cM 20 3.40 100
Fetal fissure
coloboma
4 65 cM 18 1.62 72
Lens cornea fusion 2 55 cM 23 1.95 95
Iris cornea fusion 12 5 cM 13 1.31 76
PHPV 13 0 cM 26 1.30 26
C57BL/6J loci segregating with specific types of ocular dysgenesis. Each type of dysgenesis is listed with its most significant QTL, the chromosome it was detected on,
its centi-Morgan (cM) position and log of odds (LOD). The number of dysgenic mice with a given phenotype, and the percentage of these mice homozygous for
C57BL/6J at the locus detected, are listed.
a The percentage of dysgenic mice carrying a locus was determined by dividing the number of mice that typed as homozygous C57BL/6J by the total number of
mice with this phenotype at a given marker.
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categories: Group 1, anophthalmia and microphthalmia; Group
2, fetal fissure coloboma; Group 3, corneolenticular adhesions;
Group 4, iridocorneal adhesions; Group 5, presence of PHPV;
and Group 6, unaffected. Mice with multiple sub-phenotypes
were included in multiple groups, for example if one eye was
anophthalmic and the other eye had PHPV the mouse was
included in both groups 1 and 5. Mice in groups 1–5 were
analyzed compared to wild-type and dysgenic mice with
different phenotypes (Figs. 7B–F). A highly significant asso-
ciation was found between mice in group 1 and a locus on
Chromosome 2 (P value <0.001). N2 AgrnCFP2R9 mice homo-
zygous for C57BL/6J alleles at this locus had a penetrance of
anophthalmia or microphthalmia of 35%, close to the 40% of
C57BL/6J AgrnCFP2R9 mice that have either of these pheno-
types. Furthermore, all N2 anophthalmic or microphthalmic
mice were homozygous C57BL/6J at this locus, while no mice
heterozygous at this locus were anophthalmic or microphthal-
mic. The Chromosome 2 locus is in a 16 MB interval between
the markers rs3692748 and rs3681694. Suggestive associations
were identified between phenotypic groups 2, 3, 4 and 5 and
loci on Chromosomes 4, 2, 12 and 13, respectively (Table 4).
Discussion
This study demonstrates that the overexpression of agrin
causes a spectrum of developmental eye defects. The defects are
attributable to the agrin protein itself, as the penetrance is dose
dependent and insensitive to the presence of the C-terminal CFP
fusion or the integration site of the transgene. The optic stalk
coloboma and subsequent misdifferentiation of the tissue as
retina correlate with a paucity of SHH in the developing optic
nerve. However, signaling systems beyond Shh are clearly
affected, and not all mice show Shh-related defects.
Sensitivity of the C57BL/6J genetic background
Some of the phenotypic variability may be contributed by the
C57BL/6J background, which is prone to spontaneous eye
defects at a low frequency (Smith et al., 1994), and which
provides a sensitized background for other factors that can
affect the development of the eye, such as fetal alcohol exposure(Sulik et al., 1981). However, while the propensity for eye
problems has been known for over 60 years (Chase, 1942), the
low penetrance of these defects has made genetic mapping of
the sensitizing loci impossible. Using, agrin overexpression as
the developmental challenge, we have successfully mapped one
strong sensitizing locus that predisposes C57BL/6J mice to
anophthalmia. Interestingly, Pax6 maps to this region, and
Pax6 mutations can cause microphthalmia and anophthalmia
(Ashery-Padan and Gruss, 2001). Furthermore, expansion of
PAX6 into the optic stalk occurred in AgrnCFP2R9 embryos that
showed misdifferentiation of the optic nerve as retina, con-
sistent with Pax6 defects underlying both the Agrn-induced
defects and the spontaneous defects in C57BL/6J. In prelim-
inary tests of the possible involvement of Pax6, the AgrnCFP2R9
transgene was bred to a recessive Pax6 allele, JR4326, (P.G.F.
unpublished) in a C3H/HeBir genetic background. Eye defects
were observed in all AgrnCFP2R9 F1 mice also heterozygous for
the Pax6 allele, while eyes were normal in all F1 mice carrying
only the agrin transgene or only heterozygous for the JR4326
locus (N25 mice examined). These results indicate that Pax6
may sensitize the eye to defects induced by the agrin over-
expression and are consistent with Pax6 underlying the
Chromosome 2 QTL.
Suggestive loci for other phenotypes may become significant
with further study. Importantly, treating all defects as a single
trait with varying severity did not reveal any significant linkage,
while mapping modifier loci associated with distinct pheno-
types (anophthalmia, PHPV, coloboma, etc.) gave significant
results. This suggests that the sensitivity of C57BL/6J is
polygenic. Multiple, distinct loci act to sensitize C57BL/6 to
different, independent eye phenotypes. Of course, the modifiers
identified are, by definition, those loci that sensitize C57BL/6J
to agrin overexpression. However, the similarity of the eye
defects in response to agrin overexpression and the spontaneous
defects seen in C57BL/6J suggest that the same loci may be
involved in the wild-type eye as well.
Agrin in the eye
Agrin is abundantly expressed in the wild-type eye and is a
major heparan sulfate proteoglycan in the internal limiting
membrane (Halfter, 1993; Halfter et al., 1997). This localization
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blood vessels, is consistent with the observed localization of the
transgenic agrin-CFP protein. In the chick eye, agrin is also
reported to localize to glycinergic synapses in the retina (Mann
and Kroger, 1996). Such a localization within the adult retina
has not been observed in the transgenic mice. This may reflect
species differences, antibody detection thresholds, or a depend-
ence on the developmental stage examined.
The integrity of the ILM is essential for retinal–ganglion–
cell axon-outgrowth and soma survival (Halfter et al., 2000,
2001, 2005). For instance, treatment with collagenase rapidly
and irreversibly disrupts retinal morphology. The contribution
of agrin to these functions of the ILM is unclear, but the lack of
an eye phenotype at birth in the agrin loss-of-function mice
suggests that any embryonic function must be redundant with
other ILM components. Agrin does affect outgrowth of retinal
axons (Halfter, 1996) and presynaptic differentiation (Cam-
pagna et al., 1995, 1997; Chang et al., 1997), and these effects
depend in part on heparan sulfate (Baerwald-de la Torre et al.,
2004).
HSPGs and developmental signaling in the eye
The variety of phenotypes caused by agrin overexpression is
consistent with perturbations in the function of other HSPGs in
eye development, which can have widely varying effects. The
chemical modification of HS sulfonyl groups leads to defects in
retinal axon targeting in Xenopus (Irie et al., 2002). The loss of
HS-linked forms of perlecan results in postnatal lens degener-
ation in mice (Rossi et al., 2003). Mice lacking the heparan
sulfate-2 sulfotransferase gene (Hs2st1) have an iris coloboma
(Bullock et al., 1998), and mice lacking GlcNAc N-deacetylase/
N-sulfotransferase 1 (Ndst1) have severe defects in eye develop-
ment consistent with impaired SHH and FGF signaling.
Agrin directly interacts with FGF2, and this interaction
affects neurite outgrowth (Cotman et al., 1999; Kim et al., 2003).
HS also interacts directly with SHH, although this has not been
demonstrated for agrin-associated HS chains (Rubin et al.,
2002). Consistent with direct interaction, agrin overexpression
decreases SHH in the developing optic nerve. The agrin-induced
misdifferentiation of the optic nerve also resembles the
phenotype of Vax1/Vax2 mutant mice (Mui et al., 2005). The
Vax genes control the PAX2/PAX6 boundary and are also
downstream of Shh, further implicating Shh dysfunction in this
aspect of the agrin overexpression phenotype. Furthermore, the
Vax study showed that the differentiation of the optic stalk as the
optic nerve requires the suppression of Pax6 expression, which
otherwise leads to retinal fate. This differentiation of the optic
nerve as retina is therefore a default pathway and not dependent
on signals from the surface ectoderm. Our results support this
hypothesis, since the same phenotype occurs in the agrin
transgenic mice by an independent manipulation.
It is noteworthy that agrin is localized to the structures in the
eye that are adversely affected by overexpression, suggesting a
direct role in the dysgenesis. However, it is also important to
note that the phenotype is caused by overexpression, and eye
defects are not observed in agrin knockout mice. Agrinoverexpression may therefore be interfering with the interac-
tion of other molecules to cause the phenotype. Such “non-
specific” interactions are possible between HSPGs when the
interactions are mediated by the HS groups and not by the
core proteins. For example, loss of syndecan in Drosophila
can be suppressed by overexpression of a glypican with a
similar cellular localization (Johnson et al., 2004). Further-
more, agrin sometimes carries chondroitin sulfate modification
in addition to heparan sulfate (Winzen et al., 2003), further
increasing the number of molecular interactions that may be
perturbed by agrin overexpression.
Therefore, we hypothesize that the defects we observed
are, at least in part, caused by a perturbation in heparan
sulfate function through agrin overexpression. The extent to
which these effects depend on the agrin core protein for
localization or the agrin gene for its expression pattern remain
to be determined. However, it is an intriguing possibility that
the overexpression of other HSPGs, particularly matrix bound
proteins such as perlecan, may also cause defects in eye
development.
Non-glycosaminoglycan interactions
The core protein of agrin also interacts with other extra-
cellular molecules. Prominent among these interactions are α-
dystroglycan, which interacts with the C-terminus of agrin
(Campanelli et al., 1994; Gee et al., 1994; Gesemann et al.,
1996; Hopf and Hoch, 1996), and the gamma1 chain of laminin
trimers, which interacts with the N-terminus of agrin (Denzer et
al., 1995; Kammerer et al., 1999). Disrupting the function of
laminin or dystroglycan through the overexpression of agrin
could also affect the development of the eye, as these proteins
have recently been shown to be important, based upon loss-of-
function studies (Lunardi et al., 2006; Zinkevich et al., 2006).
Furthermore, mutations in glycosyltransferases that modify
dystroglycan and eliminate its ability to interact with agrin also
cause defects in the eye (Lee et al., 2005; Michele et al., 2002).
Thus agrin's effects on eye development may extend beyond
glycosaminoglycan interactions.
Agrin is a key signaling molecule for the formation of the
neuromuscular junction. However, in vivo defects in neurode-
velopment have been found only in the cholinergic synapses of
the superior cervical ganglia in loss-of-function alleles of agrin
(Gingras et al., 2002). The overexpression of agrin causes
defects in eye development that resemble defects affecting HS
synthesis or modification. The variability of the phenotype and
the presence of multiple sensitizing loci in the C57BL/6J
background suggest that multiple developmental events are
affected by agrin overexpression. These effects could be
through HS-overabundance, perturbed core–protein interac-
tions, genetic predisposition, and even unknown environmental
and epigenetic factors such as maternal or fetal stress. However,
the high penetrance of defects in the sensitized C57BL/6J
background and the well characterized biology of agrin make
this system an excellent model for future studies on the
molecular and genetic interactions that are needed for proper
eye development.
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